التفاصيل البيبلوغرافية
| العنوان: |
Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. |
| المؤلفون: |
Bellmunt, Joaquim, Montagut, Clara, Albiol, Santiago, Carles, Joan, Maroto, Pablo, Orsola, Anna |
| المصدر: |
BJU International; Feb2007, Vol. 99 Issue 2, p274-280, 7p |
| مصطلحات موضوعية: |
RENAL cell carcinoma, INTERLEUKIN-2, PROTEIN-tyrosine kinase inhibitors, NEOVASCULARIZATION, MONOCLONAL antibodies, INTERFERONS |
| مصطلحات جغرافية: |
UNITED States, EUROPE |
| مستخلص: |
The understanding of cellular processes underlying tumour biology has allowed the development of novel molecular-targeted drugs with optimistic results in renal cell carcinoma (RCC). Mutations in the von Hippel-Lindau gene are found in 75% of sporadic RCCs, which results in upregulation of several genes involved in angiogenesis, e.g. vascular endothelial growth factor and platelet-derived growth factor. Other activated pathways in RCC are the epidermal growth factor receptor and the mTOR pathway, which regulate survival and cell growth. In addition to temsirolimus (an mTOR inhibitor) two different strategies have been studied to inhibit these targets: monoclonal antibodies, e.g. bevacizumab, and small molecule tyrosine-kinase inhibitors such as sorafenib, sunitinib and AG 013736. Phase II studies with these drugs reported substantial clinical activity in advanced RCC. Survival benefit was reported with temsirolimus, sunitinib and sorafenib in randomized trials, which led to the accelerated approval of sorafenib and sunitinib for advanced RCC by regulatory authorities in the USA and Europe. Nevertheless, as new therapies develop, new challenges arise for the optimum use of these targeted drugs. We discuss the rationale and the clinical development of these novel molecular-targeted agents, with special emphasis on updated information presented at recent meetings because of the relevance of the data reported and the potential future impact in the management of patients with RCC. [ABSTRACT FROM AUTHOR] |
|
Copyright of BJU International is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder